Nephropathy is a major cause of premature morbidity and mortality in patients with non-insulin-dependent diabetes mellitus (NIDDM). The insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme (ACE) is a genetic determinant of plasma ACE levels. Recent studies have found I/D polymorphism of the ACE gene to be associated with nephropathy in NIDDM. This association has not been evaluated in prospective studies. We, therefore, studied the relationship between ACE gene I/D polymorphism and diabetic albuminuria and glomerular filtration rate (GFR) in 83 NIDDM patients followed up for 9 years. At baseline, 29% (24 of 83) of the diabetic patients had an increased (>30 mg/24 h) urinary albumin excretion rate (UAER) and the prevalence of albuminuria at the 9-year examination was 35% (29 of 83). During the follow-up period, systolic blood pressure (p = 0.044), prevalence of hypertension (p < 0.01), and fasting blood glucose levels (p < 0.01) increased, while high-density lipoprotein cholesterol (p < 0.01) decreased. The declines of GFR during the follow-up period were 8.5, 14.1, and 16.3% within genotype groups of II, ID, and DD, respectively (p values for decreases: NS for II, <0.001 for ID, and <0.001 for DD). Patients with the DD genotype tended to have a steeper decrease of GFR, but the change was not statistically significant between the genotype groups. The increases of UAER during the follow-up period were 35.1, 8.3, and 122.4% within genotype groups of II, ID, and DD, respectively, but p values for all increases were not significant. Parallel to GFR, patients with the DD genotype tended to have a steeper increase of UAER, but the change was not statistically significant between the genotype groups. There were no differences in the ACE genotype distribution and allele frequencies between the patients with or without albuminuria either at follow-up or in cross-sectional settings. In conclusion, this 9-year follow-up study does not support the hypothesis that the ACE I/D polymorphism is a major genetic marker of diabetic nephropathy in NIDDM patients.

Keywords:
Angiotensin-converting enzyme, Gene polymorphism, Nephropathy, Non-insulin-dependent diabetes mellitus, Albuminuria, Polymerase chain reaction
1.
Mattock M, Morrish N, Viberti G, Keen H, Fithgerald A, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736–741.
2.
Mogensen C: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356–360.
3.
Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Lauritzen M, Hougaard P, Lauritzen E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J 1988;296:156–160.
4.
Gall M, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, Dijgaard A, Lauritzen M, Lauritzen E, Hougaard P, Beck-Nielsen NH, Parving HH: Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetes patients. Diabetologia 1991;34:655–661.
5.
Andersen A, Christiansen J, Andersen J, Kreiner S, Deckert T: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983;25:496–501.
6.
Viberti G, Hill R, Jarrett R, Argyrpoulos A, Mahmud U, Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i:1430–1432.
7.
Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
8.
Mathiesen E, Bonn B, Jensen T, Storm B, Deckert T: Relationship between blood pressure and urine albumin excretion in development of microalbuminuria. Diabetes 1990;39:245–249.
9.
Haneda M, Kikkawa R, Togawa M, Koya D, Kajiwara N, Uzu T, Shigeta Y: High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1992;6:181–185.
10.
Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985;82:5963–5967.
11.
Rudberg S, Persson B, Dahlquist G: Increased glomerular filtration rate as a predictor of diabetic nephropathy: An 8-year prospective study. Kidney Int 1992;41:822–828.
12.
Hostetter TH, Troy JL, Brenner MB: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410–415.
13.
Sequist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161–1165.
14.
Borch-Johnson K, Norgaard K, Hommel E: Is diabetic nephropathy an inherited complication? Kidney Int 1992;41:719–722.
15.
Erdos EG: Angiotensin I-converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363–370.
16.
Lewis E, Hunsicker L, Bain R, Rohde R: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–1462.
17.
Bjork S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effect of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986;293:471–474.
18.
Lieberman J, Sastre A: Serum angiotensin-converting enzyme: Elevations in diabetes mellitus. Ann Intern Med 1980;93:8825–8826.
19.
Hallab M, Bled F, Ebran J, Suraniti S, Girault A, Fressinaud P, Marre M: Elevated serum angiotensin I converting enzyme activity in type I, insulin-dependent diabetic subjects with persistent microalbuminuria. Acta Diabetol 1992;29:82–85.
20.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–1346.
21.
Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197–205.
22.
Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641–644.
23.
Ruiz J, Blanche H, Cohen N, Velho G, Cambien F, Cohen D, Passa P, Froguel P: Insertion/deletion polymorphism in the gene for angiotensin converting enzyme is associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994;91:3662–3665.
24.
Marre M, Bernadet P, Gallois Y, Savanger F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384–388.
25.
Doi Y, Yoshizumi H, Yoshinari M, Iino K, Yamamoto M, Ichikawa K, Iwase M, Fujishima M: Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM. Diabetologia 1996;39:97–102.
26.
Jeffers B, Estacio R, Raynolds M, Schrier R: Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 1997;52:473–477.
27.
Schmidt S, Schone N, Ritz E: Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int 1995;47:1176–1181.
28.
Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH: Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995;44:489–494.
29.
Ringel J, Beige J, Kunz R, Distler A, Sharma A: Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. Diabetologia 1997;40:193–199.
30.
Wirta O, Pasternack A, Laippala P, Turjanmaa V: Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol 1996;45:10–17.
31.
Warnick GR, Benderson J, Albers JJ: Dextran sulfate-Mg2+ precipitation for quantitation of high-density lipoprotein cholesterol; in Cooper GR (ed): Selected Method of Clinical Chemistry. Washington, American Association for Clinical Chemistry, 1983, vol 10, pp 91–99.
32.
Garnett ES, Parsons V, Veall N: Measurement of glomerular filtration rate in man using a 51Cr-edetic acid complex. Lancet 1967;i:818–819.
33.
Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992;20:1433.
34.
Odawara M, Matsunuma A, Yamashita K: Mistyping frequency of the angiotensin-converting enzyme gene polymorphism and an improved method for its avoidance. Hum Genet 1997;100:163–166.
35.
Ohno T, Kawazu S, Tomono S: Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism 1996;45:218–222.
36.
Panagiotopoulos S, Smith TJ, Aldred GP, Baker EJ, Jacklin CJ, Jerums G: Angiotensin-converting enzyme (ACE) gene polymorphism in type II diabetic patients with increased albumin excretion rate. J Diabetes Complications 1995;9:272–276.
37.
Fujisawa T, Ikegami H, Shen GQ, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J, Ohishi M, Fuji K, Fukuda M, Ogihara T: Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995;18:983–985.
38.
Powrie J, Watts GF, Ingham J, Taub N, Talmud P, Show K: Role of glycemic control in development of microalbuminuria in patients with insulin dependent diabetes. BMJ 1997;309:1608–1612.
39.
Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy: Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994;43:690–695.
40.
Miller JA, Scholey JW, Thai K, Pei YP: Angiotensin converting enzyme gene polymorphism and renal hemodynamic function in early diabetes. Kidney Int 1997;51:119–124.
41.
Wirta O, Pasternack A, Mustonen J, Koivula T, Harmoinen A: Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant 1996;11:449–456.
42.
Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow-up study. BMJ 1996;313:591–594.
43.
van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347:94–95.
44.
Niskanen L, Uusitupa M, Sarlund H, Siitunen O, Voutilainen E, Penttilä I, Pyörälä K: Microalbuminuria predicts the development of serum lipoprotein abnormalities favoring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1990;33:237–243.
45.
Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T: Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent diabetic patients: An update of the Steno studies. Diabetologia 1991;34:164–170.
46.
Back LA, Cilbert RE, Copper ME, Tsalamandris C, Jerums G: Prediction of persistent microalbuminuria in patients with diabetes mellitus. J Diabetes Complications 1993;7:67–72.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.